Citius Oncology, Inc. CTOR Noncash Merger Related Costs
Noncash Merger Related Costs at other companies
Other financials
Where this comes from
Reported directly by Citius Oncology, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NoncashMergerRelatedCosts.
The official record: Citius Oncology, Inc.’s 10-Q, filed February 13, 2026, on SEC EDGAR. View the filing →
Ask your AI about Citius Oncology, Inc.'s noncash merger related costs.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Citius Oncology, Inc.'s noncash merger related costs?
- Citius Oncology, Inc. (CTOR) reported noncash merger related costs of $2.75M in Q4 2025.
- What does noncash merger related costs mean?
- Captures expenses incurred during business combinations that do not involve an immediate cash outflow, such as the amortization of acquired intangibles or stock-based compensation adjustments. Monitoring these costs helps investors distinguish between operational performance and accounting charges resulting from corporate restructuring. It is essential for normalizing earnings to reflect true cash-based operational health.